Analyst consensus rating
AN2 Therapeutics Analyst Rating: Strong Buy
ANTX is rated Strong Buy by 2 analysts with a $9.00 target. As of 2026-08-24.
Direct answer
AN2 Therapeutics's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.00.
Forecast evidence checked August 24, 2026.
Get free AN2 Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.81
- Average price target
- $9.00
- High price target
- $9.00
- Low price target
- $9.00
- Low target gap
- +54.9%
- Target upside
- +54.9%
- High target gap
- +54.9%
- Target range width
- 0%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AN2 Therapeutics?
AN2 Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $9.00.
How far are AN2 Therapeutics's low and high targets from the recorded price?
The low target implies +54.9%, while the high target implies +54.9%.
How many analysts are included in AN2 Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is AN2 Therapeutics's target upside or downside calculated?
The average target of $9.00 is divided by the recorded price of $5.81, then one is subtracted to produce +54.9%. This does not guarantee a future return.
When was AN2 Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.